Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1955 1
1956 1
1957 2
1958 3
1959 1
1961 2
1962 5
1963 4
1964 1
1965 8
1966 2
1967 6
1968 2
1969 8
1970 1
1971 8
1972 5
1974 7
1975 6
1976 8
1977 3
1978 11
1979 9
1980 4
1981 5
1982 9
1983 11
1984 17
1985 13
1986 11
1987 9
1988 15
1989 12
1990 16
1991 17
1992 19
1993 17
1994 17
1995 26
1996 17
1997 16
1998 27
1999 33
2000 22
2001 20
2002 19
2003 27
2004 33
2005 29
2006 27
2007 44
2008 41
2009 51
2010 47
2011 47
2012 47
2013 34
2014 33
2015 41
2016 50
2017 60
2018 51
2019 63
2020 70
2021 98
2022 82
2023 84
2024 68
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,458 results

Results by year

Filters applied: . Clear all
Page 1
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Furusawa S, Nomoto H, Yokoyama H, Suzuki Y, Tsuzuki A, Takahashi K, Miya A, Kameda H, Cho KY, Takeuchi J, Nagai S, Taneda S, Kurihara Y, Nakamura A, Atsumi T; SWITCH-SEMA 2 study group. Furusawa S, et al. Among authors: nagai s. Diabetes Obes Metab. 2024 Mar;26(3):961-970. doi: 10.1111/dom.15393. Epub 2023 Dec 11. Diabetes Obes Metab. 2024. PMID: 38073422 Clinical Trial.
Chromatin potentiates transcription.
Nagai S, Davis RE, Mattei PJ, Eagen KP, Kornberg RD. Nagai S, et al. Proc Natl Acad Sci U S A. 2017 Feb 14;114(7):1536-1541. doi: 10.1073/pnas.1620312114. Epub 2017 Jan 30. Proc Natl Acad Sci U S A. 2017. PMID: 28137832 Free PMC article.
Outcome of sarcoidosis.
Nagai S, Handa T, Ito Y, Ohta K, Tamaya M, Izumi T. Nagai S, et al. Clin Chest Med. 2008 Sep;29(3):565-74, x. doi: 10.1016/j.ccm.2008.03.006. Clin Chest Med. 2008. PMID: 18539245 Review.
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: nagai se. Breast Cancer. 2024 Jul;31(4):621-632. doi: 10.1007/s12282-024-01575-5. Epub 2024 Apr 20. Breast Cancer. 2024. PMID: 38642245 Free PMC article.
One-year lung function decline in sarcoidosis.
Tanizawa K, Handa T, Nagai S, Ikezoe K, Kubo T, Yokomatsu T, Ueda S, Fushimi Y, Ogino S, Hirai T, Izumi T. Tanizawa K, et al. Among authors: nagai s. Respir Investig. 2024 Jan;62(1):9-12. doi: 10.1016/j.resinv.2023.09.005. Epub 2023 Nov 3. Respir Investig. 2024. PMID: 37925884
Smoking-related interstitial lung diseases.
Nagai S, Hoshino Y, Hayashi M, Ito I. Nagai S, et al. Curr Opin Pulm Med. 2000 Sep;6(5):415-9. doi: 10.1097/00063198-200009000-00005. Curr Opin Pulm Med. 2000. PMID: 10958232 Review.
Interleukin-4 and breast cancer.
Nagai S, Toi M. Nagai S, et al. Breast Cancer. 2000;7(3):181-6. doi: 10.1007/BF02967457. Breast Cancer. 2000. PMID: 11029795 Review.
Long-term survival and functional outcomes of laparoscopic surgery for clinical stage I ultra-low rectal cancers located within 5 cm of the anal verge: A prospective phase II trial (Ultimate trial).
Ito M, Tsukada Y, Watanabe J, Fukunaga Y, Hirano Y, Sakamoto K, Hamamoto H, Yoshimitsu M, Horie H, Matsuhashi N, Kuriu Y, Nagai S, Hamada M, Yoshioka S, Ohnuma S, Hayama T, Otsuka K, Inoue Y, Ueda K, Toiyama Y, Maruyama S, Yamaguchi S, Tanaka K, Suzuki M, Naitoh T, Ando K, Watanabe M; Ultimate Trial Group. Ito M, et al. Among authors: nagai s. Ann Surg. 2024 Apr 1;281(2):304-11. doi: 10.1097/SLA.0000000000006290. Online ahead of print. Ann Surg. 2024. PMID: 38557445 Free PMC article.
1,458 results